FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296532273> ?p ?o ?g. }

• W4296532273 endingPage "S407" @default.
• W4296532273 startingPage "S406" @default.
• W4296532273 abstract "Despite advances in treatment options, multiple myeloma remains incurable. REGN5458 is a BCMAxCD3 bispecific antibody under investigation in relapsed/refractory multiple myeloma (RRMM): ongoing Phase 1/2 trial (NCT03761108).To describe updated safety, overall response, and response durability in patients treated with REGN5458 in the Phase 1 part.The Phase 1 part follows a modified 3+3 dose-escalation design (4+3).Eligible patients with progressive RRMM, who were double- or triple-refractory, or intolerant to prior lines of systemic therapy, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 antibody, were included.Sixteen weekly infusions of REGN5458 monotherapy, then every two weeks until disease progression.Primary objectives were to assess safety, tolerability, and occurrence of dose-limiting toxicities of REGN5458, and to determine a recommended Phase 2 dose regimen. The objective response rate by modified International Myeloma Working Group criteria was a key secondary objective.At data cut-off (September 30, 2021), 73 patients were treated with REGN5458 in the dose-escalation cohort, with full doses ranging from 3-800 mg. The median age at enrollment was 64 years (range, 41-81). As per the Revised International Staging System, stages were 1, 2, or 3 in 15.0%, 57.5%, and 23.3% of patients, respectively. Patients had a median of five prior lines of systemic therapy (range, 2-17), with 89% of patients being triple-refractory. The median duration of follow-up was 3.0 months (range, 0.7-22.1). The most common treatment-emergent adverse events (TEAEs) were fatigue (45.2%), cytokine release syndrome (CRS) (38.4%), pyrexia (35.6%), and nausea (32.9%). There were no Grade ≥3 CRS or Grade ≥3 neurotoxicity events, and no treatment discontinuation due to CRS. Grade 3 and 4 TEAEs were reported in 31 (42.5%) and 24 patients (32.9%), respectively. The most common Grade 3/4 TEAEs were hematologic (39.0%). Responses were observed at all dose levels. Amongst patients treated at the 200-800 mg dose levels, the response rate was 75% (n=18/24). The median duration of response was not reached.REGN5458 shows early, deep, and durable responses with a manageable safety profile in triple or greater-refractory patients with RRMM. This study is funded by Regeneron." @default.
• W4296532273 created "2022-09-21" @default.
• W4296532273 creator A5006919907 @default.
• W4296532273 creator A5026731813 @default.
• W4296532273 creator A5028046297 @default.
• W4296532273 creator A5030703994 @default.
• W4296532273 creator A5031344736 @default.
• W4296532273 creator A5034791164 @default.
• W4296532273 creator A5042703700 @default.
• W4296532273 creator A5043429440 @default.
• W4296532273 creator A5049306094 @default.
• W4296532273 creator A5054661384 @default.
• W4296532273 creator A5064399162 @default.
• W4296532273 creator A5064581434 @default.
• W4296532273 creator A5068969389 @default.
• W4296532273 creator A5071375525 @default.
• W4296532273 creator A5071551404 @default.
• W4296532273 creator A5079116736 @default.
• W4296532273 creator A5086332908 @default.
• W4296532273 creator A5088696429 @default.
• W4296532273 date "2022-10-01" @default.
• W4296532273 modified "2023-10-17" @default.
• W4296532273 title "MM-087 Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma" @default.
• W4296532273 doi "https://doi.org/10.1016/s2152-2650(22)01591-9" @default.
• W4296532273 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36164142" @default.
• W4296532273 hasPublicationYear "2022" @default.
• W4296532273 type Work @default.
• W4296532273 citedByCount "2" @default.
• W4296532273 countsByYear W42965322732023 @default.
• W4296532273 crossrefType "journal-article" @default.
• W4296532273 hasAuthorship W4296532273A5006919907 @default.
• W4296532273 hasAuthorship W4296532273A5026731813 @default.
• W4296532273 hasAuthorship W4296532273A5028046297 @default.
• W4296532273 hasAuthorship W4296532273A5030703994 @default.
• W4296532273 hasAuthorship W4296532273A5031344736 @default.
• W4296532273 hasAuthorship W4296532273A5034791164 @default.
• W4296532273 hasAuthorship W4296532273A5042703700 @default.
• W4296532273 hasAuthorship W4296532273A5043429440 @default.
• W4296532273 hasAuthorship W4296532273A5049306094 @default.
• W4296532273 hasAuthorship W4296532273A5054661384 @default.
• W4296532273 hasAuthorship W4296532273A5064399162 @default.
• W4296532273 hasAuthorship W4296532273A5064581434 @default.
• W4296532273 hasAuthorship W4296532273A5068969389 @default.
• W4296532273 hasAuthorship W4296532273A5071375525 @default.
• W4296532273 hasAuthorship W4296532273A5071551404 @default.
• W4296532273 hasAuthorship W4296532273A5079116736 @default.
• W4296532273 hasAuthorship W4296532273A5086332908 @default.
• W4296532273 hasAuthorship W4296532273A5088696429 @default.
• W4296532273 hasConcept C121332964 @default.
• W4296532273 hasConcept C121608353 @default.
• W4296532273 hasConcept C126322002 @default.
• W4296532273 hasConcept C141071460 @default.
• W4296532273 hasConcept C142424586 @default.
• W4296532273 hasConcept C143998085 @default.
• W4296532273 hasConcept C197934379 @default.
• W4296532273 hasConcept C2776063141 @default.
• W4296532273 hasConcept C2776364478 @default.
• W4296532273 hasConcept C2777063308 @default.
• W4296532273 hasConcept C2777701055 @default.
• W4296532273 hasConcept C2778375690 @default.
• W4296532273 hasConcept C2780850621 @default.
• W4296532273 hasConcept C2781413609 @default.
• W4296532273 hasConcept C29730261 @default.
• W4296532273 hasConcept C3875195 @default.
• W4296532273 hasConcept C71924100 @default.
• W4296532273 hasConcept C87355193 @default.
• W4296532273 hasConceptScore W4296532273C121332964 @default.
• W4296532273 hasConceptScore W4296532273C121608353 @default.
• W4296532273 hasConceptScore W4296532273C126322002 @default.
• W4296532273 hasConceptScore W4296532273C141071460 @default.
• W4296532273 hasConceptScore W4296532273C142424586 @default.
• W4296532273 hasConceptScore W4296532273C143998085 @default.
• W4296532273 hasConceptScore W4296532273C197934379 @default.
• W4296532273 hasConceptScore W4296532273C2776063141 @default.
• W4296532273 hasConceptScore W4296532273C2776364478 @default.
• W4296532273 hasConceptScore W4296532273C2777063308 @default.
• W4296532273 hasConceptScore W4296532273C2777701055 @default.
• W4296532273 hasConceptScore W4296532273C2778375690 @default.
• W4296532273 hasConceptScore W4296532273C2780850621 @default.
• W4296532273 hasConceptScore W4296532273C2781413609 @default.
• W4296532273 hasConceptScore W4296532273C29730261 @default.
• W4296532273 hasConceptScore W4296532273C3875195 @default.
• W4296532273 hasConceptScore W4296532273C71924100 @default.
• W4296532273 hasConceptScore W4296532273C87355193 @default.
• W4296532273 hasLocation W42965322731 @default.
• W4296532273 hasLocation W42965322732 @default.
• W4296532273 hasOpenAccess W4296532273 @default.
• W4296532273 hasPrimaryLocation W42965322731 @default.
• W4296532273 hasRelatedWork W2051109119 @default.
• W4296532273 hasRelatedWork W2052365909 @default.
• W4296532273 hasRelatedWork W2118112957 @default.
• W4296532273 hasRelatedWork W2129596076 @default.
• W4296532273 hasRelatedWork W2474837444 @default.
• W4296532273 hasRelatedWork W3126730168 @default.
• W4296532273 hasRelatedWork W3217566318 @default.
• W4296532273 hasRelatedWork W4297237848 @default.
• W4296532273 hasRelatedWork W4311628015 @default.
• W4296532273 hasRelatedWork W1941943869 @default.

• next